finding,pubmed_id,finding_id
"The use of tyrosine kinase inhibitors like gefitinib, commonly used to treat non-small cell lung cancer, can exacerbate pulmonary fibrosis in mice models of lung damage (Ishii et al., 2006).",PMC5507769,PMC5507769_0
"Constitutive ubiquitous expression of some epidermal growth factor (EGF) ligands, resulting in constant EGF activation, leads to the activation of fibrosis (Hardie et al., 1996).",PMC5507769,PMC5507769_1
"Mice deficient in transforming growth Factor alpha (TGF-α), a key ligand for the EGF receptor (EGFR), are protected from chronic lung disease in models of lung damage (Madtes et al., 1999).",PMC5507769,PMC5507769_2
"Modulators of TGF-β signaling, a hallmark of many fibrotic diseases, lower TGF-β levels in the host and have effects at lowering fibrosis (Akhurst and Hata, 2012).",PMC5507769,PMC5507769_3
"The use of EGFR inhibitors, like erlotinib and its family members, can reverse or inhibit fibrosis development in animal models (Hardie et al., 1997).",PMC5507769,PMC5507769_4
